Stoltenborg J K, Puglisi C V, Rubio F, Vane F M
J Pharm Sci. 1981 Nov;70(11):1207-12. doi: 10.1002/jps.2600701107.
A high-performance liquid chromatographic (HPLC) assay was developed for the determination of the ratios of the (S)-(+) and (R)-(-) enantiomers of the anti-inflammatory drug carprofen in blood, urine, and feces. The procedure relies on: (a) extraction and purification of carprofen from biological fluids, (b) reaction of carprofen with (S)-(-)-alpha-methylbenzylamine to form the two diastereomeric (S)-(-)-alpha-methylbenzylamides via the 1,1'-carbonyldiimidazole intermediate, (c) purification of the reaction mixture by extraction of the diastereomeric derivatives into hexane at pH 11, and (d) analysis of the diastereomeric derivatives by HPLC with UV detection. The (S)-(+): (R)-(-) ratios in the blood of three subjects receiving single 100-mg oral doses of carprofen were greater than unity up to 16 hr after dosing. The mean +/- SD of the ratios in the early blood samples (0.5, 1, and 2 hr) was 1.21 +/- 0.09, while the mean of the ratios in the later blood samples (4,6,8,12, and 16 hr) was slightly higher (1.48 +/- 0.17). The blood level fall off curves for the (S)-(+) and (R)-(-) enantiomers were similar in each of the three subjects for the 4-16 hr period. The carprofen enantiomers were excreted stereoselectively by humans. An excess of the (S)-(+) enantiomer relative to the (R)-(-) enantiomer was excreted in the urine as the ester glucuronide, while unchanged (R)-(-) enantiomer predominated in the feces. The total urinary plus fecal excretion of the enantiomers (0-96 hr) revealed only a slight excess of the (S)-(+) enantiomer over the (R)-(-) enantiomer, which amounted to 2.1-49% of the dose. Since the amount of carprofen (free and glucuronide) excreted in 96 hr by the three subjects only accounted for 62-72% of the dose, no definitive statement could be made relative to the possible inversion of the carprofen chiral center.
建立了一种高效液相色谱(HPLC)法,用于测定血液、尿液和粪便中抗炎药卡洛芬的(S)-(+)和(R)-(-)对映体的比例。该方法基于:(a)从生物流体中提取和纯化卡洛芬;(b)卡洛芬与(S)-(-)-α-甲基苄胺反应,通过1,1'-羰基二咪唑中间体形成两种非对映体(S)-(-)-α-甲基苄酰胺;(c)通过在pH 11下将非对映体衍生物萃取到己烷中来纯化反应混合物;(d)通过带紫外检测的HPLC分析非对映体衍生物。三名单次口服100 mg卡洛芬的受试者血液中的(S)-(+):(R)-(-)比例在给药后16小时内均大于1。早期血液样本(0.5、1和2小时)中该比例的平均值±标准差为1.21±0.09,而后期血液样本(4、6、8、12和16小时)中该比例的平均值略高(1.48±0.17)。在4-16小时期间,三名受试者中(S)-(+)和(R)-(-)对映体的血药浓度下降曲线相似。卡洛芬对映体在人体内的排泄具有立体选择性。相对于(R)-(-)对映体,过量的(S)-(+)对映体以酯葡糖醛酸苷的形式排泄到尿液中,而未变化的(R)-(-)对映体在粪便中占主导。对映体的总尿排泄量加粪便排泄量(0-96小时)显示,(S)-(+)对映体仅略多于(R)-(-)对映体,占剂量的2.1%-49%。由于三名受试者在96小时内排泄的卡洛芬(游离和葡糖醛酸苷)量仅占剂量的62%-72%,因此无法就卡洛芬手性中心可能的转化做出明确说明。